Anti-VEGF therapy can inhibit ovarian cancer progression, metastasis, and malignant ascites formation promoted by the release of VEGF from CAFs, along with various other cell types [170]; however, synchronous anti-PDGF treatment might be necessary to target CAFs resistant to VEGF-neutralizing agents [171]. The gene discussed is VEGFA; the disease is ovarian cancer.